IL315941A - Uses of farnesoid x receptor agonists - Google Patents

Uses of farnesoid x receptor agonists

Info

Publication number
IL315941A
IL315941A IL315941A IL31594124A IL315941A IL 315941 A IL315941 A IL 315941A IL 315941 A IL315941 A IL 315941A IL 31594124 A IL31594124 A IL 31594124A IL 315941 A IL315941 A IL 315941A
Authority
IL
Israel
Prior art keywords
compound
patient
amino acid
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
IL315941A
Other languages
English (en)
Hebrew (he)
Inventor
Thomas Capozza
Original Assignee
Intercept Pharmaceuticals Inc
Thomas Capozza
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intercept Pharmaceuticals Inc, Thomas Capozza filed Critical Intercept Pharmaceuticals Inc
Publication of IL315941A publication Critical patent/IL315941A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
IL315941A 2022-04-21 2023-04-21 Uses of farnesoid x receptor agonists IL315941A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263333287P 2022-04-21 2022-04-21
US202263381752P 2022-10-31 2022-10-31
PCT/US2023/019448 WO2023205447A2 (en) 2022-04-21 2023-04-21 Uses of farnesoid x receptor agonists

Publications (1)

Publication Number Publication Date
IL315941A true IL315941A (en) 2024-11-01

Family

ID=88420596

Family Applications (1)

Application Number Title Priority Date Filing Date
IL315941A IL315941A (en) 2022-04-21 2023-04-21 Uses of farnesoid x receptor agonists

Country Status (10)

Country Link
US (1) US20250288600A1 (cg-RX-API-DMAC10.html)
EP (1) EP4511012A4 (cg-RX-API-DMAC10.html)
JP (1) JP2025513289A (cg-RX-API-DMAC10.html)
KR (1) KR20250006156A (cg-RX-API-DMAC10.html)
CN (1) CN119136794A (cg-RX-API-DMAC10.html)
AU (1) AU2023257308A1 (cg-RX-API-DMAC10.html)
CA (1) CA3249500A1 (cg-RX-API-DMAC10.html)
IL (1) IL315941A (cg-RX-API-DMAC10.html)
MX (1) MX2024012966A (cg-RX-API-DMAC10.html)
WO (1) WO2023205447A2 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024097247A1 (en) * 2022-10-31 2024-05-10 Intercept Pharmaceuticals, Inc. Uses of farnesoid x receptor agonists
US12677339B2 (en) * 2022-11-14 2026-07-07 Intel Corporation Sensing by proxy (SBP) termination frame with termination control field

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015314830B2 (en) * 2014-09-12 2021-01-07 Tobira Therapeutics, Inc. Cenicriviroc combination therapy for the treatment of fibrosis
PE20180690A1 (es) * 2015-04-27 2018-04-23 Intercept Pharmaceuticals Inc Composiciones de acido obeticolico y metodos de uso
EA038632B1 (ru) * 2016-03-11 2021-09-27 Интерсепт Фармасьютикалз, Инк. 7,11-дигидрокси-6-этил-5-холан-24-овая кислота и фармацевтические композиции на ее основе для лечения или предупреждения заболевания или состояния, опосредованных фарнезоидным х-рецептором (fxr)
IL271343B2 (en) * 2017-06-23 2023-12-01 Intercept Pharmaceuticals Inc Methods and intermediates for the preparation of bile acid derivatives

Also Published As

Publication number Publication date
CN119136794A (zh) 2024-12-13
JP2025513289A (ja) 2025-04-24
AU2023257308A1 (en) 2024-10-10
EP4511012A2 (en) 2025-02-26
WO2023205447A3 (en) 2024-04-04
MX2024012966A (es) 2024-11-08
KR20250006156A (ko) 2025-01-10
WO2023205447A2 (en) 2023-10-26
EP4511012A4 (en) 2026-06-24
CA3249500A1 (en) 2023-10-26
US20250288600A1 (en) 2025-09-18

Similar Documents

Publication Publication Date Title
JP5869469B2 (ja) 鉄が病因に関与する肝臓疾患の処置
AU729463B2 (en) Treatment of cardiomyopathy
JP3721196B2 (ja) 新生物疾患および自己免疫疾患の治療または予防のためのマグネシウムベースの製品の使用
JP2025143324A5 (cg-RX-API-DMAC10.html)
JP2000511190A (ja) 外傷に起因する出血に見舞われたヒトにおけるｂｐｉタンパク質産物の治療用途
JP2022542830A (ja) Ｅｙｐ００１を使用した改善された処置
JP2025513289A5 (cg-RX-API-DMAC10.html)
WO2023231730A2 (zh) 使用mazdutide的治疗方法
EP3976053A1 (en) Compositions and methods for treating metabolic disease
JP3838034B2 (ja) Ｃ型肝炎治療効果の改善剤及びその応用
US6348495B1 (en) Method for treating celiac disease
JP3885135B2 (ja) Ｃ型又は非ｂ非ｃ型肝炎ウイルスによる肝機能異常の改善剤
WO2024023745A1 (en) Treatment for acute organ injury using cd39, recombinant cd39
AU747885B2 (en) Treatment of disease states
JP5034944B2 (ja) インターフェロン作用物質の活性増強剤
CN115335044A (zh) 使用pkm2激活剂治疗纤维化的方法
JP2006515011A (ja) Ｈｃｖ併用療法
Lahaye et al. Vanishing pulmonary hypertension in mixed connective tissue disease
JP2003527420A (ja) 鬱血性心不全の治療方法
JP2010208946A (ja) 関節リウマチの予防・治療剤
US5750501A (en) Method and composition for treatment of patients having decompensated liver disease
JPWO2006033453A1 (ja) インターフェロン作用物質の活性増強剤
Gross Nonresponders to previous chronic hepatitis C treatment
JP3691533B2 (ja) 抗動脈硬化ペプチド
US20050187181A1 (en) Use of purine nucleosides to stimulate Na/K ATPase and to treat or prevent shock